Evidence map›Paper›PMID 38874164›Full record

ArticleThe ISME journal2024

Resistance towards and biotransformation of a Pseudomonas-produced secondary metabolite during community invasion.

Morten L Hansen, Zsófia Dénes, Scott A Jarmusch, Mario Wibowo, Carlos N Lozano-Andrade, Ákos T Kovács, Mikael L Strube, Aaron J C Andersen, Lars Jelsbak

Abstract read
In one paragraph

Article in The ISME journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Warfare among rice sheath pathogens:Applied and environmental microbiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. ISME communications · 2025
    Article
  13. Article
  14. Co-existence of two antibiotic-producing marine bacteria:Applied and environmental microbiology · 2024
    Article
  15. Article
  16. Does regulation hold the key to optimizing lipopeptide production inFrontiers in bioengineering and biotechnology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Morten L HansenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0003-3927-2751
Zsófia DénesDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0003-0087-1052
Scott A JarmuschDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0002-1021-1608
Mario WibowoDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0002-5739-0949
Carlos N Lozano-AndradeDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0003-2805-4505
Ákos T KovácsDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0002-4465-1636
Mikael L StrubeDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0003-0905-5705
Aaron J C AndersenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0002-3876-7480
Lars JelsbakDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads bldg. 221, DK-2800 Kgs Lyngby, Denmark.ORCID 0000-0002-5759-9769

Funding

Center of Excellence for Microbial Secondary MetabolitesDanish National Research Foundation DNRF137Novo Nordisk Foundation NNF19OC0055625
6 · The paper itself

Abstract

The role of antagonistic secondary metabolites produced by Pseudomonas protegens in suppression of soil-borne phytopathogens has been clearly documented. However, their contribution to the ability of P. protegens to establish in soil and rhizosphere microbiomes remains less clear. Here, we use a four-species synthetic community (SynCom) in which individual members are sensitive towards key P. protegens antimicrobial metabolites (DAPG, pyoluteorin, and orfamide A) to determine how antibiotic production contributes to P. protegens community invasion and to identify community traits that counteract the antimicrobial effects. We show that P. protegens readily invades and alters the SynCom composition over time, and that P. protegens establishment requires production of DAPG and pyoluteorin. An orfamide A-deficient mutant of P. protegens invades the community as efficiently as wildtype, and both cause similar perturbations to community composition. Here, we identify the microbial interactions underlying the absence of an orfamide A mediated impact on the otherwise antibiotic-sensitive SynCom member, and show that the cyclic lipopeptide is inactivated and degraded by the combined action of Rhodococcus globerulus D757 and Stenotrophomonas indicatrix D763. Altogether, the demonstration that the synthetic community constrains P. protegens invasion by detoxifying its antibiotics may provide a mechanistic explanation to inconsistencies in biocontrol effectiveness in situ.

Indexed as

BiotransformationPseudomonasSecondary MetabolismSoil MicrobiologyAnti-Bacterial AgentsMicrobial InteractionsMicrobiotaPhenolsPhloroglucinolPyrrolesRhizosphere2,4-diacetylphloroglucinolAnti-Bacterial AgentsPhenolsPhloroglucinolpyoluteorinPyrrolesbiotransformationDAPGmicrobial interactionsorfamide APseudomonas invasionpyoluteorinsecondary metabolitesSynCom

Identifiers

PMID38874164
PMCPMC11203913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.